Pharming has submitted its oral phosphoinositide 3-kinase delta (PI3Kδ) inhibitor leniolisib for approval in the EU as a treatment for activated PI3K delta syndrome (APDS), an ultra-rare disease ...
Infinity Pharmaceuticals has gained access to Intellikine's portfolio of phosphoinositide 3-kinase-δ (PI3Kδ) and PI3Kγ inhibitors for inflammation and oncology indications through an exclusive ...
Prior to her career in biopharmaceuticals, she was an Associate Partner with McKinsey & Company where she advised senior management in life sciences and healthcare on a range of strategy, organization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback